Despite much recent progress, prostate cancer continues to represent a major cause of
cancer-related mortality and morbidity in men. Since early studies on the role of the …

Epigenetic modifications play a key role in the patho-physiology of prostate cancer. Histone
deacetylases (HDACs) play major roles in prostate cancer progression. HDACs are part of a …

Loss-of-function mutations in the nuclear factor erythroid-2–related factor 2 (Nrf2) inhibitor
Kelch-like ECH-associated protein 1 (Keap1) result in increased Nrf2 activity in non–small …

Hypomethylation of CpG dinucleotides in genomic DNA was one of the first somatic
epigenetic alterations discovered in human cancers. DNA hypomethylation is postulated to …

Nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) is a transcription factor which regulates
the expression of many cytoprotective genes. In the present study, we found that the …

BACKGROUND The clinical success of the nucleoside analogs 5‐aza‐cytidine (5‐azaC)
and 5‐aza‐2′ deoxycytidine (5‐aza‐dC) as DNA methyltransferase (DNMT) inhibitors has …

Epigenetic silencing of gluthathione‐S‐transferase pi (GSTP1) is recognized as being a
molecular hallmark of human prostate cancer. We investigated the effects of green tea …

BACKGROUND: Aberrant DNA methylation is a hallmark of cancer, and DNA
methyltransferase inhibitors have demonstrated clinical efficacy in hematologic …

DNA hypermethylation is a common epigenetic alteration in human prostate cancer and is
considered to contribute to development of this disease. Accumulating data suggest that …

Prostate cancer (PC) is the most commonly diagnosed neoplasm and the third most
common cause of cancer-related death amongst men in the Western world. PC is a clinically …